Acinetobacter baumannii Ventilator-Associated Pneumonia: Clinical Efficacy of Combined Antimicrobial Therapy and in vitro Drug Sensitivity Test Results

Frontiers in Pharmacology
Yuqin HuangMingli Tu

Abstract

Objective: To evaluate therapeutic efficacy of different combined antimicrobial treatments against Acinetobacter baumannii ventilator-associated pneumonia (VAP). Methods: Clinical outcomes were retrospectively analyzed to elucidate the efficacy of four combined antimicrobial regimens. The chessboard and micro broth dilution methods determined the minimum inhibitory concentrations (MICs) of four antiseptic drugs singly used and combined two drugs against 36 isolates of multidrug-resistant (MDR) A. baumannii. Results: The incidence of VAP was approximately 6.9% (237/3424) between January 1, 2015 and December 31, and 35.9% (85/237) of the cases were caused by A. baumannii. Among these cases, 60 belonged to AB-VAP, for whom antimicrobial treatment plan was centralized and clinical data was complete. Moreover, all 60 strains of A. baumannii were MDR bacteria from reports microbiological laboratory. Resistance rate was lowest for amikacin (68.3%) and ampicillin sulbactam (71.7%). Resistance rate for imipenem increased from 63.2 to 90.9% during the 3 years. However, in these 60 cases of AB-VAP, the combination between 4 antibiotics was effective in most cases: the effective rate was 75% (18/24) for sulbactam combined with etilmicin, 7...Continue Reading

References

Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Mar 24, 2005·Intensive Care Medicine·José Garnacho-MonteroF J Jiménez-Jiménez
Mar 11, 2008·International Journal of Antimicrobial Agents·Irene GalaniHelen Giamarellou
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lisa L Maragakis, Trish M Perl
May 28, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joel Fishbain, Anton Y Peleg
Jun 29, 2010·Current Opinion in Infectious Diseases·José Garnacho-Montero, Rosario Amaya-Villar
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John G MuscedereDaren K Heyland
Dec 7, 2010·International Journal of Antimicrobial Agents·Ioannis K NeonakisEfthimia Petinaki
Jul 27, 2011·Antimicrobial Agents and Chemotherapy·Hua ZhouYunsong Yu
Oct 7, 2011·The Journal of Hospital Infection·P EspinalJ Vila
Dec 14, 2011·Critical Care : the Official Journal of the Critical Care Forum·Leonardo PaganiStephan Harbarth
Feb 9, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Marin H KollefFrank R Ernst
Apr 3, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paritosh PrasadCharles Natanson
May 31, 2012·BMJ : British Medical Journal·John D Hunter
Jun 30, 2012·Current Opinion in Infectious Diseases·Lila BouadmaJean-Christophe Lucet
Aug 30, 2012·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Guangsheng PeiYuxia Sun
Nov 2, 2012·Scandinavian Journal of Infectious Diseases·Nak-Hyun KimMyoung-Don Oh
Mar 23, 2013·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Aiman El-SaedYaseen M Arabi
Jun 14, 2013·Critical Care Medicine·Mariano EsperattiAntoni Torres
Jan 24, 2014·The New England Journal of Medicine·Yun WangJames Battles
Apr 15, 2014·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Jingjing XiaXiangqun Fang
Jan 30, 2016·Critical Care : the Official Journal of the Critical Care Forum·Matteo BassettiRichard G Wunderink
Jul 16, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andre C KalilJan L Brozek
Oct 16, 2016·American Journal of Infection Control·Víctor Daniel RosenthalUNKNOWN Remaining authors
Jan 18, 2018·Current Opinion in Infectious Diseases·Matteo BassettiMaddalena Peghin
Feb 2, 2018·Antimicrobial Resistance and Infection Control·Zeina A KanafaniSouha S Kanj

❮ Previous
Next ❯

Methods Mentioned

BETA
bronchoalveolar

Software Mentioned

Excel
SPSS

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.